Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7 Tumor-Agnostic 4 Gynecologic 3 Lymphoid 2 Head & Neck 2 Genitourinary 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 NET 1 Endocrine 1 CNS 1 Breast 1

Conditions

Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 16 Magnetic Resonance Spectroscopy 14 gallium Ga 68 dotatate 9 Specimen Handling 8 Everolimus 8 pembrolizumab 7 cabozantinib 6 Cisplatin 6 fluorodopa F 18 5 Etoposide 5 trametinib 4 surufatinib 4 lanreotide 4 dabrafenib 4 cemiplimab 4 X-Rays 4 Temozolomide 4 Nivolumab 4 Lutetium-177 4 Lutetium 4 Fluorodeoxyglucose F18 4 Carboplatin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 olaparib 3 lenvatinib 3 copper dotatate CU-64 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Surveys and Questionnaires 3 Somatostatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Data Collection × Endocrine × Clear all

NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting

Intestinal Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡